Page last updated: 2024-08-25

bexarotene and decitabine

bexarotene has been researched along with decitabine in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Abboud, CN; Cashen, AF; Dipersio, JF; Jacoby, M; Niu, H; Pusic, I; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P	1

Reviews

1 review(s) available for bexarotene and decitabine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for bexarotene and decitabine

Article	Year
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. American journal of hematology, 2014, Volume: 89, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Bexarotene; Decitabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Mice; Middle Aged; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Tumor Cells, Cultured	2014

Article

Year

A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.

American journal of hematology, 2014, Volume: 89, Issue:8

Topics: Administration, Oral; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Bexarotene; Decitabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Mice; Middle Aged; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Tumor Cells, Cultured

2014

Other Studies

1 other study(ies) available for bexarotene and decitabine

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013